

<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		ATTORNEY'S DOCKET NUMBER
		782_232
		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
		<b>10/540989</b>
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/JP2004/000002	05 January 2004 (05.01.04)	06 January 2003 (06.01.03)
TITLE OF INVENTION		
ANTIPSYCHOTIC MOLECULAR-TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR		
APPLICANT(S) FOR DO/EO/US		
NAWA, Hiroyuki; and MIZUNO, Makoto		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</li> <li>4. <input type="checkbox"/> The US has been elected (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)). <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>		
<b>Items 11 to 20 below concern document(s) or information included:</b> <ol style="list-style-type: none"> <li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input type="checkbox"/> An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input checked="" type="checkbox"/> A Preliminary Amendment.</li> <li>14. <input checked="" type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</li> <li>15. <input type="checkbox"/> A Substitute Specification.</li> <li>16. <input type="checkbox"/> A Power of Attorney and/or Change of Address Letter.</li> <li>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</li> <li>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</li> <li>19. <input type="checkbox"/> A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).</li> <li>20. <input checked="" type="checkbox"/> Other items or information: PCT/IB/306 International Publication (front page only) PCT/ISA/210</li> </ol>		

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>10/540989</b>		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER 782_232	
The following fees are submitted:				Calculations	PTO Use Only
21. <input checked="" type="checkbox"/> Basic National Fee ..... \$300.00				\$ 300.00	
22. <input checked="" type="checkbox"/> Examination Fee If International Preliminary Examination Report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) ..... \$100.00 All other situations ..... \$ 200.00				\$ 200.00	
23. <input checked="" type="checkbox"/> Search Fee Search Fee has been paid on the International Application to USPTO as ISA ... \$100.00 International Search Report prepared and provided to the Office ..... \$400.00 All other situations ..... \$ 500.00				\$ 400.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$ 900.00</b>	
[ ] Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250.00 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 sheets or fraction thereof (round up to a whole number)	Rate		
53 - 100 =	0/50 =	0	x \$250.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	16 - 20 =	0	x \$50.00		
Independent Claims	3 - 3 =	0	x \$200.00		
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360.00		
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$ 1,030.00</b>	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$ 515.00	
<b>SUBTOTAL =</b>				<b>\$ 515.00</b>	
Processing fee of \$130.00 for furnishing the English Translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	
<b>TOTAL NATIONAL FEE =</b>				<b>\$ 515.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$ 515.00</b>	
				Amount to be refunded:	\$
				Amount to be charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$515.00 to cover the above fees is enclosed. b. [ ] Please charge my Deposit Account No. 50-1446 in the amount of \$_____ to cover the above fees. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1446. A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Customer No. 025191					
Burr & Brown P.O. Box 7068 Syracuse, NY 13261-7068			Stephen P. Burr Reg. No. 32,970		
Telephone: (315) 233-8300 Facsimile: (315) 233-8320					

Practitioner's Docket No.: 782\_232

20/540989  
JC17 Rec'd PCT/PTO 28 JUN 2005  
PATENT

**IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

International Application No.: PCT/JP2004/000002  
International Filing Date: 05 January 2004 (05.01.04)  
Earliest Priority Date Claimed: 06 January 2003 (06.01.03)  
Title of Invention: ANTIPSYCHOTIC MOLECULAR-TARGETING EPIDERMAL  
GROWTH FACTOR RECEPTOR  
Applicant(s) for DO/EO/US: NAWA, Hiroyuki; and MIZUNO, Makoto

**EXPRESS MAIL CERTIFICATE**

"Express Mail" label number: EV 363537774 US  
Date of Deposit: 28 June 2005


I hereby state that the following *attached* paper or fee

Transmittal Letter to the US/DO/EO Concerning a Filing Under 35 U.S.C. 371  
and National Phase Patent Application

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee"  
service under 37 CFR §1.10, on the date indicated above and is addressed to:

**Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450.**

Elizabeth A. VanAntwerp

  
Signature of person mailing paper or fee